Hyperliquid news

Hyperliquid's upcoming November token unlock will release 2.66% of its supply, sparking fears of dilution and a potential drop to $20 if a head-and-shoulders pattern confirms. Analysts note controlled sell-off by large holders, while some view short-term volatility as a yield-farm opportunity. Despite supply pressure, on-chain fee revenue tops $2.2M in 24h, giving the DEX a strong balance sheet. If fees fund buy-backs or liquidity programs, the impact could be mitigated. Long-term value hinges on translating revenue into holder returns, with the unlock serving as a key test rather than a definitive end.

21Shares filed with the SEC to launch an ETF tracking Hyperliquid’s HYPE token, aiming to passively follow its price without leverage. The trust will be held by CSC Delaware, with Coinbase Custody and BitGo as custodians, and may stake holdings within legal limits. The filing comes amid a surge of altcoin ETF applications; the SEC is reviewing over 150. Recent launches such as Bitwise Solana ETF saw strong first‑day volume, indicating growing demand for regulated crypto exposure beyond Bitcoin and Ethereum.

21Shares has filed with the SEC to launch an ETF that would track the Hyperliquid DEX’s native token, HYPE, potentially becoming the second U.S. exchange‑traded fund focused on the cryptocurrency after Bitwise’s proposal. The filing comes as the SEC reviews more than 90 crypto‑focused ETF applications, and it cites HYPE’s status as the 16th‑largest crypto by market cap at $12.7 billion and a recent price of about $47.55. The fund would use Coinbase and BitGo as custodians.

Hyperliquid launched equity perpetuals, generating almost $100 million in trading volume within 24 hours while open interest topped $66 million. The move sparked debate over the viability of on‑chain equity derivatives. Proponents argue the product turns the traditional equities market into a 24/7, borderless, transparent ecosystem that could replace zero‑day options, meeting the high demand for leveraged exposure and potentially outgrowing stablecoins. Critics warn of liquidity shortages, regulatory uncertainty, and the risk of manipulation in low‑liquidity environments. Without robust risk‑management and compliance safeguards, the innovation faces skepticism and heightened oversight.

A runaway bot on the Lighter DEX sent Hyperliquid's HYPE token from $47 to almost $98 in under a minute, exposing thin liquidity on decentralized exchanges. The bot aggressively cleared the order book, creating a temporary price spike that was later removed from the front‑end chart to avoid scaling issues, though on‑chain data confirms the event. A trader claimed to have profited about $600,000 by selling a large HYPE position during the distortion, highlighting the potential gains from vigilant market monitoring. The incident has prompted calls for built‑in safeguards such as circuit breakers, volatility throttles and liquidity thresholds to prevent similar anomalies in low‑volume DEXs.

HYPE, the native token of Hyperliquid, surged over 13% after its Robinhood listing, reaching $40.87 and breaking out above its multi‑week falling wedge and the 200‑day EMA, a bullish reversal signal that could lift the price toward $56.50 (≈40% gain) by November. The breakout was accompanied by a sharp rise in trading volume, indicating fresh buying interest and a possible new uptrend; analysts target around $50. However, a retreat below the 200‑day EMA would invalidate the bullish setup and could drag HYPE back to the wedge’s lower trendline near $32‑34, with some forecasters warning of a fall to $20, urging long‑term holders to stay cautious.

Hyperliquid Strategies filed an S‑1 to raise up to $1 billion, offering 160 million shares, to expand its Hyperliquid (HYPE) token treasury amid growing institutional demand. The move follows a pending merger of Sonnet BioTherapeutics and SPAC Rorschach I LLC and a Nasdaq listing bid under symbol PURR. The filing helped lift HYPE 8 % in the last 24 h, with the token trading around $38.26. Hyperliquid has spent $644.64 million in revenue and bought back 21.36 million tokens, while a new unlock schedule will release ~10 million HYPE each month until 2027, though analysts remain bullish on long‑term prospects.

Hyperliquid Strategies, the pending merger entity of Nasdaq-listed Sonnet BioTherapeutics and SPAC Rorschach I LLC, has filed an S‑1 to raise up to $1 billion by offering 160 million shares. The capital will be used to buy more HYPE tokens and cover other corporate costs, with Chardan Capital Markets advising. With 12.6 million HYPE already held (worth ~470 million) and $305 million in cash, the new funding could make Hyperliquid the largest corporate HYPE holder. The announcement triggered an ~8% rally to $37.73, while broader crypto markets slipped 0.6%.

Hyperliquid’s HYPE token surged nearly 7% in a market that fell, buoyed by a reverse merger that will create Hyperliquid Strategies Inc. The deal, led by Nasdaq‑listed Sonnet BioTherapeutics, will bring a $583 million HYPE treasury and a $1 billion credit facility, signalling institutional confidence in the token. MetaMask has added native support for Hyperliquid swaps, while rival BNB Chain’s Aster fell 7.6%. The move underscores growing interest in perpetual futures and suggests HYPE could benefit from added scarcity and long‑term demand.

Solana's Yakovenko said he was just “messing around” with AI and never meant for the code to be public.